Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
Tempus AI (NASDAQ: TEM) announced nine abstracts accepted for presentation at the Society for Immunotherapy of Cancer's 39th Annual Meeting in November 2024. Key highlights include two poster presentations: one validating a novel multi-omic algorithm for predicting immune checkpoint inhibitor (ICI) treatment outcomes using the Immune Profile Score (IPS), and another analyzing the cost-effectiveness of molecular biomarkers combined with CT imaging for treatment response monitoring. The second study, involving 4,147 cancer patients, demonstrated significant cost savings when using molecular biomarkers alongside CT imaging, particularly in small cell lung cancer treated with ICI-chemotherapy.
Tempus AI (NASDAQ: TEM) ha annunciato nove abstract accettati per la presentazione al 39° Congresso Annuale della Società per l'Immunoterapia del Cancro che si terrà a novembre 2024. Tra i punti salienti ci sono due presentazioni poster: una che valida un innovativo algoritmo multi-omico per prevedere gli esiti del trattamento con inibitori dei checkpoint immunitari (ICI) utilizzando il punteggio di profilo immunitario (IPS), e l'altra che analizza il rapporto costo-efficacia dei biomarcatori molecolari combinati con l'imaging CT per il monitoraggio della risposta al trattamento. Il secondo studio, che ha coinvolto 4.147 pazienti affetti da cancro, ha dimostrato significativi risparmi economici quando si utilizzano biomarcatori molecolari insieme all'imaging CT, in particolare nel caso del cancro polmonare a piccole cellule trattato con chemioterapia-ICI.
Tempus AI (NASDAQ: TEM) anunció nueve resúmenes aceptados para presentación en la 39ª Reunión Anual de la Sociedad para la Inmunoterapia del Cáncer que se llevará a cabo en noviembre de 2024. Los aspectos más destacados incluyen dos presentaciones de póster: una que valida un nuevo algoritmo multi-ómico para predecir los resultados del tratamiento con inhibidores de puntos de control inmunitarios (ICI) utilizando el Puntuación de Perfil Inmunológico (IPS), y otra que analiza el costo-efectividad de los biomarcadores moleculares combinados con imágenes por TC para el monitoreo de la respuesta al tratamiento. El segundo estudio, que involucró a 4,147 pacientes con cáncer, demostró un ahorro de costos significativo al utilizar biomarcadores moleculares junto con imágenes por TC, particularmente en cáncer de pulmón de células pequeñas tratado con quimioterapia-ICI.
템퍼스 AI (NASDAQ: TEM)은 2024년 11월 암 면역 요법 사회의 제39회 연례 회의에서 발표된 아홉 개의 초록을 발표했습니다. 주요 하이라이트 중 두 개의 포스터 프레젠테이션이 포함됩니다: 하나는 면역 프로파일 점수(IPS)를 사용하여 면역 체크포인트 억제제(ICI) 치료 결과를 예측하는 혁신적인 다중 오믹 알고리즘을 검증하며, 다른 하나는 치료 반응 모니터링을 위한 CT 이미징과 결합된 분자 바이오마커의 비용 효율성을 분석합니다. 4,147명의 암 환자를 포함한 두 번째 연구는 분자 바이오마커와 함께 CT 이미징을 사용할 때 특히 ICI-화학요법으로 치료받는 소세포 폐암에서 상당한 비용 절감 효과를 보여주었습니다.
Tempus AI (NASDAQ: TEM) a annoncé neuf résumés acceptés pour présentation lors de la 39e Réunion Annuelle de la Société pour l'Immunothérapie du Cancer prévue en novembre 2024. Par ailleurs, deux présentations par affiche sont à souligner : l'une valide un nouvel algorithme multi-omique pour prédire les résultats du traitement par inhibiteurs des points de contrôle immunitaires (ICI) en utilisant le Score de Profil Immunitaire (IPS), et l'autre analyse le rapport coût-efficacité des biomarqueurs moléculaires associés à l'imagerie par CT pour le suivi de la réponse au traitement. La deuxième étude, impliquant 4 147 patients atteints de cancer, a démontré des économies de coûts significatives en utilisant des biomarqueurs moléculaires avec l'imagerie CT, en particulier dans le cas du cancer du poumon à petites cellules traité par chimiothérapie-ICI.
Tempus AI (NASDAQ: TEM) kündigte neun Abstracts an, die für die Präsentation bei der 39. Jahrestagung der Gesellschaft für Immuntherapie von Krebs im November 2024 akzeptiert wurden. Zu den wichtigsten Höhepunkten gehören zwei Posterpräsentationen: eine, die einen neuartigen multi-omischen Algorithmus validiert, um die Ergebnisse der Behandlung mit Immun-Checkpoint-Inhibitoren (ICI) mithilfe des Immune Profile Score (IPS) vorherzusagen, und eine andere, die die Kosten-Effektivität von molekularen Biomarkern in Kombination mit CT-Bildgebung zur Überwachung der Therapieansprechen analysiert. Die zweite Studie, die 4.147 Krebspatienten einbezog, zeigte erhebliche Kosteneinsparungen bei der Verwendung molekularer Biomarker zusammen mit CT-Bildgebung, insbesondere bei kleinzelligem Lungenkrebs, der mit ICI-Chemotherapie behandelt wurde.
- Development of new Immune Profile Score (IPS) algorithm for predicting treatment outcomes
- Study demonstrates cost savings when combining molecular biomarkers with CT imaging
- Large-scale validation using data from 4,147 advanced cancer patients
- None.
Insights
The abstracts reveal significant progress in Tempus' AI-driven precision medicine initiatives. The development of the Immune Profile Score (IPS) algorithm, combining DNA and RNA sequencing data, represents a breakthrough in predicting immunotherapy outcomes. This could potentially reduce failed treatments and healthcare costs while improving patient care.
The cost-effectiveness study of CT imaging patterns is particularly noteworthy. By demonstrating substantial cost savings when combining molecular biomarkers with CT imaging, especially in SCLC cases, this research could influence clinical practice guidelines and insurance coverage policies. This has implications for both healthcare providers and payers, potentially creating new revenue streams for Tempus' diagnostic services.
While these research presentations validate Tempus' technological capabilities, the real commercial impact will depend on clinical adoption and payer acceptance of these novel approaches. The findings could accelerate the company's market penetration in the growing precision oncology space.
“Presenting our latest research is a vital opportunity to showcase the advancements Tempus is making in harnessing the power of data and AI to drive immunotherapy innovation,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “We are committed to working with the oncology community to share insights that can accelerate the development of more effective, personalized therapies and contribute to the improvement of outcomes for patients.”
This year, highlights of Tempus’ poster presentations include:
-
Poster Presentation (#188): Clinical validation of a novel multi-omic algorithm for stratifying outcomes in a real-world cohort of metastatic solid cancer patients treated with immune checkpoint inhibitors
- Session Date & Time: Saturday, November 9, 2024; 9:00 a.m. - 8:30 p.m. CT
- Location: George R. Brown Convention Center; Exhibit Halls AB
- Overview: This study aimed to predict patient outcomes to immune checkpoint inhibitors (ICI) by developing an integrated DNA/RNA ICI biomarker. A de-identified pan-cancer cohort from the Tempus multimodal real-world database was utilized to develop and validate the Immune Profile Score (IPS) algorithm that leverages Tempus xT (DNA sequencing) and xR (RNA sequencing). The researchers found that IPS status can be used to stratify patient cohorts and prognosticate ICI-treatment response.
-
Poster Presentation (#1352): Impact of timing of real-world CT imaging on cost-effectiveness of a molecular biomarker for treatment response monitoring of immunotherapy
- Session Date & Time: Saturday, November 9, 2024; 9:00 a.m. - 8:30 p.m. CT
- Location: George R. Brown Convention Center; Exhibit Halls AB
- Overview: The research team sought to model the impact of Computed Tomography (CT) imaging patterns on the clinical utility and cost-effectiveness of a molecular biomarker for treatment response monitoring (TRM) compared to imaging. The team analyzed real-world imaging patterns from a cohort of 4,147 advanced cancer patients treated with immune checkpoint inhibitors (ICI) across five solid tumor types. The study found significant variability in CT scan intervals between cancer types and treatments. Incorporating these patterns into a microsimulation model, the team demonstrated that using the molecular biomarker in conjunction with CT imaging provided substantial cost savings and reduced inappropriate therapy compared to imaging alone, with the most benefit observed in small cell lung cancer (SCLC) treated with ICI-chemotherapy.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of these abstracts; the contributions of these abstracts to the larger scientific community, and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241108624897/en/
Tempus Communications
Erin Carron
media@tempus.com
Source: Tempus AI, Inc.
FAQ
What research will Tempus (TEM) present at SITC 2024?
How many patients were included in Tempus (TEM) CT imaging study?
When will Tempus (TEM) present at the SITC Annual Meeting 2024?
